{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-24-000106","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.754276+00:00","generated_at":"2026-06-02T19:19:32.710001+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zentalis Q1 cash $489M; multiple azenosertib data readouts H2 2024–2025","bullets":["Cash, equivalents & marketable securities $489.0M (incl $56.7M Immunome stock); projected runway to mid-2026.","R&D expense $49.6M (up $1M YoY); G&A $15.7M (down $0.7M). Quarterly net loss not disclosed.","Key milestones: Phase 1 osteosarcoma data at 2024 ASCO; DENALI (PROC) topline H1 2025; TETON (USC) topline H2 2025.","Interim CFO Cam Gallagher appointed April 5, 2024; search for permanent CFO underway.","Azenosertib development on track with partnerships (GSK, Pfizer); registration-enabling trial in PSOC planned for 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-24-000106","json":"https://secwatch.observer/filing/0001725160-24-000106.json","markdown":"https://secwatch.observer/filing/0001725160-24-000106.md","text":"https://secwatch.observer/filing/0001725160-24-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000106/0001725160-24-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000106/zntl-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:19:32.710001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29c7d0cb5772aa64464af251f20dcb581f010fad","claim":"Zentalis Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 7, 2024, Zentalis Pharmaceuticals, Inc. (the \"Company\") announced its financial results for the quarter ended March 31, 2024 and commented on certain business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000106/0001725160-24-000106-index.htm","confidence":0.96,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}